Alexandra Fingesten, MD
Geriatric Medicine · New York, NYNPI 1972658185
Payments from drug & device makers
Across 521 payments — averaging $17.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Alkermes, Inc.$1K
- GSK$781
- Novo Nordisk$749
- AstraZeneca$493
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$456
- plus $3K from 28 others
What the payments were for
- Food & beverage$9,079100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 163 | $2,618 |
| Alkermes, Inc. | 56 | $1,021 |
| GSK | 45 | $781 |
| Novo Nordisk | 47 | $749 |
| AstraZeneca | 27 | $493 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 29 | $456 |
| Bausch Health US, LLC | 20 | $298 |
| Pfizer | 12 | $259 |
| Lilly USA, LLC | 12 | $239 |
| Axsome Therapeutics, Inc. | 9 | $212 |
| Johnson & Johnson | 12 | $205 |
| Teva Pharmaceuticals USA, Inc. | 11 | $194 |
| Supernus Pharmaceuticals, Inc. | 8 | $156 |
| Amgen | 7 | $146 |
| Eisai Inc. | 7 | $140 |
| Otsuka America Pharmaceutical, Inc. | 7 | $118 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $117 |
| Neurocrine Biosciences, Inc. | 5 | $116 |
| Vanda Pharmaceuticals Inc. | 4 | $97 |
| Astellas Pharma US Inc | 5 | $89 |
| Lundbeck LLC | 4 | $82 |
| MDD US Operations, LLC | 5 | $79 |
| E.r. Squibb & Sons, L.L.C. | 4 | $72 |
| Ironwood Pharmaceuticals, Inc | 3 | $60 |
| USWM, LLC | 2 | $59 |
| Gilead | 2 | $57 |
| Scilex Pharmaceuticals Inc. | 2 | $40 |
| Almatica Pharma LLC | 1 | $25 |
| Corium, LLC | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Indivior Inc. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $15 |
| Acadia Pharmaceuticals Inc | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVITROL$125
How this compares
$9,079 in reported general payments places this provider in the 95th percentile of 400 geriatric medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 65 | $85,888 |
| MounjaroTirzepatide | 51 | $64,098 |
| EliquisApixaban | 75 | $63,291 |
| XareltoRivaroxaban | 58 | $52,672 |
| VraylarCariprazine Hcl | 31 | $43,184 |
| VivitrolNaltrexone Microspheres | 23 | $38,033 |
| MyrbetriqMirabegron | 42 | $28,083 |
| LinzessLinaclotide | 37 | $26,620 |
| RybelsusSemaglutide | 12 | $22,521 |
| JanuviaSitagliptin Phosphate | 22 | $18,852 |
| OxycontinOxycodone Hcl | 12 | $11,627 |
| Ethacrynic Acid | 20 | $11,134 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 17 | $7,375 |
| Dexlansoprazole DrDexlansoprazole | 19 | $5,578 |
| Levothyroxine Sodium | 347 | $4,233 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $749 | $108,41077 claims |
| AbbVieVraylar, Linzess, Synthroid | $2,618 | $72,120120 claims |
| Lilly USA, LLCMounjaro | $239 | $64,09851 claims |
| PfizerEliquis | $259 | $63,29175 claims |
| Johnson & JohnsonXarelto | $205 | $52,67258 claims |
| Alkermes, Inc.Vivitrol | $1,021 | $38,03323 claims |
| Astellas Pharma US IncMyrbetriq | $89 | $28,08342 claims |
| AstraZenecaBevespi Aerosphere | $493 | $7,37517 claims |
| GSKIncruse Ellipta | $781 | $3,60712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 400 geriatric medicine providers in New York.
Other geriatric medicine in New York
- Howard FillitNew York$42K
- Lisa BabitzNew York$6K
- Laszlo FeherNew York$4K
- Eric ManheimerNew York$3K
- Sharda RamsaroopNew York$2K
- Sofya KleynNew York$2K
- Eileen CallahanNew York$2K
- Sharon BrangmanSyracuse$1.8M
- Adam CohenGreat Neck$223K
- Amit SaxenaBronx$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.